Meropenem ROTAC for CDK6 Exatecan mesylate inhibits topoisomerase I

Exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting religation of DNA breaks

The inhibitory effect of Ikarisoside A resulted in decrease of osteoclast-specific genes like matrix metalloproteinase 9 (MMP9)

is more than 100 nM

BCA Disodium

10aH-benzo[g]pteridine-2

Meropenem ROTAC for CDK6 Exatecan mesylate inhibits topoisomerase IMeropenem is an ultra broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem and Meronem. Other brand names include Zwipen (India, Marketed by Nucleus) Mepem